Reviewer’s report

Title: Daptomycin Therapy for Osteomyelitis: A Retrospective Study

Version: 2 Date: 10 April 2012

Reviewer: Abhay Dhand

Reviewer’s report:

Major Compulsory Revisions:

1. While it is nice to have epidemiological and safety data regarding all the patients who fulfilled the set definition of osteomyelitis and were treated with daptomycin, the outcome data should only be evaluated for/limited to 18 patients (daptomycin monotherapy, osteomyelitis and gram positive organism on culture). Furthermore interesting would be to know how many of these 18 patients failed therapy, what were their characteristics, how many of these patients received further oral therapy etc.

Since this article focuses exclusively on the use of daptomycin, it would be interesting to know the factors leading to success and failure associated with daptomycin therapy without being all the added confounding factors (multiple antibiotics, no organism available in 17 patients, surgery, duration of antibiotics, gram negative organisms etc.).

2. Based on above, discussion on dosage of daptomycin (4 vs. 6 mg/kg) and clinical outcomes cannot be interpreted in a meaningful way.

3. Table 1:
   hematogenous spread in 12 patients, but blood culture positive only in 5 pts.?

4. Page 4, line 7: is this MSSA osteomyelitis?

5. Page 4, line 16: the sentence appears incomplete.

6. Page 4, line 21: This outcome data is in/for which infections?

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

ON SPEAKERS BUREAU OF CUBIST, PFIZER